Targets › MRC1
1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Apr 2027.
Mediates the endocytosis of glycoproteins by macrophages. Binds both sulfated and non-sulfated polysaccharide chains.; FUNCTION: (Microbial infection) Acts as a phagocytic receptor for bacteria, fungi and other pathogens.; FUNCTION: (Microbial infection) Acts as a receptor for Dengue virus envelope protein E..; FUNCTION: (Microbial infection) Interacts with Hepatitis B virus envelope protein. (UniProt, P22897)
Open in Phaseline: the race on MRC1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Universitair Ziekenhuis Brussel | 68GaNOTA-Anti-MMR-VHH2 Macrophage Mannose Receptor (MMR) targeting radiotracer for PET imaging | MRC1 | Phase 2 | Non-small Cell Lung Cancer | Apr 2027 |
Non-small Cell Lung Cancer (1)
small molecule (1)
Universitair Ziekenhuis Brussel (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.